Microbiome Therapeutics LLC, of Broomfield, Colo., said it completed a $1.3 million bridge financing to support completion of two ongoing clinical studies and preparations for further clinical trials of lead product NM504, a microbiome modulator in development for Type II diabetes and prediabetes. NM504 is being studied in two placebo-controlled, double-blind, proof-of-concept trials.